PosteG., “The Case for Genomic Patenting,”Nature, 378 (1995): 534–36; DollJ., “The Patenting of DNA,”Science, 280 (1998): 689–90.
2.
National Institutes of Health, Report of the National Institutes of Health (NIH) Working Group on Research Tools, at <http://www.nih.gov/news/researchtools/> (last visited September 9, 2003).
3.
HellerM.EisenbergR., “Can Patents Deter Innovation? The Anticommons in Biomedical Research,”Science, 280 (1998): 698–701.
Delphion Intellectual Property Network, IP Search, at <http://www.delphion.com> (last visited September 9, 2003).
6.
MoweryD.C., “The Growth of Patenting and Licensing by U.S. Universities: An Assessment of the Effects of the Bayh-Dole Act of 1980,”Research Policy, 30 (2001): 99–119, at 116.
7.
35 U.S.C.§ 202(c)(7)(D) (2002).
8.
SchisselA.MerzJ.F.ChoM.K., “Survey Confirms Fears About Licensing of Genetic Tests,”Nature, 402 (1999): 118.
Personal Communication from Theodore J. Roumel to author (J.F. Merz) (February 22, 2002).
12.
HenryM.R., “DNA Patent and Licensing,”Science, 297 (2002): 1279.
13.
ThomasS.M., “Ownership of the Human Genome,”Nature380 (1996): 387–88; ThomasS.M., “Public-Sector Patents on Human DNA,”Nature, 388 (1997): 709: ThomasS.M.HopkinsM.M.BradyM., “Shares in the Human Genome — The Future of Patenting DNA,”National Biotechnology, 20 (2002): 1185–88.
14.
WalshJ.AroraA.CohenW., The Patenting of Research Tools and Biomedical Invention, paper presented at the Conference on New Research on the Operation and Effects of the Patent System, National Academy of Science, Washington, D.C., October 22, 2001; see Henry, supra note 12.
15.
See Mowery, supra note 6.
16.
RaiA.K., “Regulating Scientific Research: Intellectual Property Rights and the Norms of Science,”Northwestern University Law Review, 94 (1999): 77–152, at 112.
17.
KatzD.MerzJ.F., “Patents and Licensing, Policy, Patenting of Inventions Developed with Public Funds,” in MehlmanM.J.MurrayT., eds., Encyclopedia of Ethical, Legal, and Policy Issues in Biotechnology (New York: John Wiley & Sons, 2000): 854–66.